Skip to main content
×
×
Home

Antipsychotic polypharmacy: review of mechanisms, mortality and management

  • Julie Langan (a1) and Polash Shajahan (a2)
Summary
Summary

Antipsychotic polypharmacy is an increasingly encountered clinical scenario. This review considers the reasons behind antipsychotic polypharmacy and the patterns of its use. We also consider the evidence of effectiveness of combined therapy v. monotherapy and the rationale behind the potentially beneficial combinations that are used. The potential dangers of antipsychotic polypharmacy are also discussed and the limited research regarding switching from polypharmacy to monotherapy is reviewed. Some provisional recommendations regarding antipsychotic polypharmacy are proposed.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antipsychotic polypharmacy: review of mechanisms, mortality and management
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Antipsychotic polypharmacy: review of mechanisms, mortality and management
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Antipsychotic polypharmacy: review of mechanisms, mortality and management
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Polash Shajahan (polash.shajahan@lanarkshire.scot.nhs.uk)
Footnotes
Hide All

See editorial, pp. 41–43, and original paper, pp. 44–46, this issue.

Declaration of interest

P.S. has received honoraria and hospitality from various pharmaceutical firms including Bristol-Myers Squibb, AstraZeneca, Lilly and Janssen-Cilag.

Footnotes
References
Hide All
1 Sheppard C, Collins L, Fiorentino D, Fracchia J, Merlis S. Polypharmacy in psychiatric treatment. Incidence at a state hospital. Curr Therap Res 1969; 11: 765–74.
2 Keks NA, Alston K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896901.
3 Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (suppl): S3540.
4 Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008; 69: 240–5.
5 Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60: 425–6.
6 Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323–30.
7 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Practice Algorithms and Pathways to Care. NICE, 2002.
8 British Medical Association, Royal Pharmaceutical Society. British National Formulary, March issue. BMJ Books & Pharmaceutical Press, 2008.
9 Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines (9th ed). Informa, 2007.
10 Royal College of Psychiatrists. Prescribing Observatory for Mental Health. Royal College of Psychiatrists (http://www.rcpsych.ac.uk/T1%20info%20leaflet.pdf).
11 Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130–6.
12 Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569–73.
13 Kotler M, Stous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19: 23–6.
14 Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472–82.
15 Yagcioclu AE, Akbdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 6372.
16 Gibson A, Patel NC, Lauriello J, Buckley P. Anti-psychotic combinations: blind step or logical? Curr Psychiatry 2008; 7: 41–8.
17 Taylor D, Mir S, Mace S, Whiskey E. Co-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcome. Psychiatr Bull 2002; 26: 170–2.
18 Correll C, Frederickson A, Kane J, Manu P. Does antipsychotic polypharmacy the risk for metabolic syndrome? Schizophr Res 2007; 89: 91100.
19 Thompson C. The use of high-dose antipsychotic medication. Br J Psychiatry 1994; 164: 448–58.
20 Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic co-prescribing. J Clin Psychiatry 2004; 65: 1597–600.
21 Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002; 28: 105–9.
22 Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55–9.
23 Waddington JL, Yousseff HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9.
24 Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004; 65: 715–20.
25 Ray W, Chung C, Murray KT, Hall K, Stein M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35.
26 Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavkan J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up study. BMJ 2006; 333: 224–30.
27 Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004; 192: 1927.
28 Bralet MC, Yon V, Loas G, Noisette C. Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale 2000; 26: 3241.
29 Chen A. Noncompliance in community psychiatry: a review of clinical interventions. Hosp Community Psychiatry 1991; 42: 282–7.
30 Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122–7.
31 Suzuki T, Uchida H, Tanaka K, Nomura K, Takano H, Tanabe A, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004; 7: 133–42.
32 Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 361–9.
33 Kawai NA, Yamakawa YB, Matsuzaka HA, Baba HA, Tachikawa AC, Hori HD, et al. Switching from high-dose of multiple neuroleptic treatments to the single atypical neuroleptic regimen (the second report): What are the risks for psychotic exacerbations? Int Clin Psychopharmacology 2005; 20: A15.
34 Soni SD, Sampath G, Shah A, Krska J. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand 1992; 85: 354–9.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×